01 March 2017
News and Views
Links and Services
The latest issue of Inflammatory Bowel Diseases examines balancing and communicating the risks and benefits of biologics in pediatric IBD.
Anti–tumor necrosis factor agents are now considered to be a vital component of the treatment alg
Email this page to a colleague
GastroHep.com is a Blackwell Publishing registered trademark
© 2017 Wiley-Blackwell and GastroHep.com and contributors